Studies On The Anti-hepatic Fibrosis Of Bicyclol And Its Active Mechanism

China is a country with a large population suffered from viral hepatitis, particularly viral hepatitis B. Due to latent development of viral hepatitis and the lack of effective therapeutics, hepatitis virus causes a large population with chronic hepatic diseases. If chronic hepatic diseases persisted in, and then hepatic fibrosis (HF) occurred. About 20% of the patients will develop into hepatic cirrhosis after 5-20 years, and some of them finally develop into hepatic cellular carcinoma (HCC) which threats the life of many people.HF represents the wound healing response of the liver to diverse repeated liver injuries, and is characterized by increase of deposition and altered composition of extra-cellular matrix (ECM) in liver. Hepatic stellate cells (HSCs) are the main cell type responsible for the ECM production in liver, and collagen type I, III are the most abundant among ECM. HF is a pivotal and necessary stage to cirrhosis, and the current investigation showed that HF even cirrhosis at early stage may be reversible. However, there is no acceptable therapy at present. Therefore, the prevention of HF has a very important significance both in theory and in practice.Bicyclol is a novel anti-hepatitis drug innovated by our institute, and now is widely used in the treatment of patients with chronic viral hepatitis in China. Bicyclol markedly reduced the elevated serum amino transaminases (ALT, AST), and also returned the marker of hepatitis virus such as HBVDNA and HBeAg from positive to negative in about 20% patients. In view of the close relation of HF with HBV, the authors thought that whether bicyclol has therapeutic effect on HF? The goal of this subject was to study the prophylactic and therapeutic effect of bicyclol on experimental HF in mice, so as to provide theoretical evidence for clinical trial of bicyclol on liver fibrosis of patients with HBV. Therefore, we established two kinds...